Is Omnitrope Approved for Short Stature in Children?
Yes, Omnitrope (somatropin) is FDA-approved for treating growth failure in children with idiopathic short stature (ISS), defined as height more than 2.25 standard deviations below the mean for age and sex without identifiable cause.[1] The approval, granted in 2006, allows use in prepubertal children aged 4 and older whose epiphyses are not closed, at doses up to 0.47 mg/kg/week subcutaneously.[1][2]
How Does It Work for Short Stature?
Omnitrope is a recombinant human growth hormone that stimulates linear growth by promoting cartilage proliferation in the growth plates of long bones. In ISS trials, children gained an average of 5.3 cm in predicted adult height after 2-7 years of treatment, though individual results vary based on age at start, bone age, and adherence.[2][3]
What Are the Requirements for Use?
Treatment requires confirmed ISS diagnosis via auxology, bone age X-ray, and exclusion of other causes like GH deficiency or Turner syndrome. Baseline IGF-1 levels and monitoring every 6-12 months are standard. Therapy stops at epiphyseal closure or age 16 if no response (less than 2.5 cm/year growth).[1][2]
Common Concerns from Parents and Doctors
Growth acceleration averages 8-10 cm in the first year but slows over time, with final height gains often modest (3-7 cm).[3] Long-term data show no increased cancer risk in ISS patients, but monitoring for scoliosis, glucose intolerance, and slipped capital femoral epiphysis is required.[1]
Who Makes Omnitrope and When Do Patents Expire?
Sandoz (a Novartis division) manufactures Omnitrope as a biosimilar to Genotropin. Key U.S. patents expired in 2014-2017, enabling competition; check DrugPatentWatch.com for latest expiry details and generic entrants.[4]
Alternatives for Pediatric Short Stache
- Norditropin or Genotropin: Similar GH products for ISS, with comparable efficacy.[2]
- Nutropin AQ: Approved for ISS but requires refrigeration.
- Non-GH options: Aromatase inhibitors or letrozole off-label for delaying puberty, though less studied.[3]
[1] FDA Label: Omnitrope (somatropin) prescribing information, 2023.
[2] Cohen P, et al. N Engl J Med 2008;358:1739-48 (ISS approval trial).
[3] Pediatric Endocrine Society guidelines on GH therapy, 2020.
[4] DrugPatentWatch.com: Omnitrope patents and exclusivity.